BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36165231)

  • 1. CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT/c-Myc-driven ribosome biogenesis.
    Mohapatra P; Mohanty S; Ansari SA; Shriwas O; Ghosh A; Rath R; Majumdar SKD; Swain RK; Raghav SK; Dash R
    FASEB J; 2022 Oct; 36(10):e22566. PubMed ID: 36165231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
    Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT3- and GSK3β-mediated Mcl-1 regulation modulates TPF resistance in oral squamous cell carcinoma.
    Maji S; Shriwas O; Samal SK; Priyadarshini M; Rath R; Panda S; Das Majumdar SK; Muduly DK; Dash R
    Carcinogenesis; 2019 Mar; 40(1):173-183. PubMed ID: 30395230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
    Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
    Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of RNA polymerase I and mTORC1/2 synergize to combat oral squamous cell carcinoma.
    Shi S; Luo H; Wang L; Li H; Liang Y; Xia J; Wang Z; Cheng B; Huang L; Liao G; Xu B
    Biomed Pharmacother; 2021 Jan; 133():110906. PubMed ID: 33190037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
    Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
    Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
    Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m
    Shriwas O; Priyadarshini M; Samal SK; Rath R; Panda S; Das Majumdar SK; Muduly DK; Botlagunta M; Dash R
    Apoptosis; 2020 Apr; 25(3-4):233-246. PubMed ID: 31974865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RRBP1 rewires cisplatin resistance in oral squamous cell carcinoma by regulating Hippo pathway.
    Shriwas O; Arya R; Mohanty S; Mohapatra P; Kumar S; Rath R; Kaushik SR; Pahwa F; Murmu KC; Majumdar SKD; Muduly DK; Dixit A; Prasad P; Nanda RK; Dash R
    Br J Cancer; 2021 Jun; 124(12):2004-2016. PubMed ID: 33762722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.
    Sudo S; Kajiya H; Okano S; Sasaki M; Katsumata Y; Ohno J; Ikebe T; Hiraki A; Okabe K
    Cancer Sci; 2020 Apr; 111(4):1113-1123. PubMed ID: 32012401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma.
    Sasaya T; Kubo T; Murata K; Mizue Y; Sasaki K; Yanagawa J; Imagawa M; Kato H; Tsukahara T; Kanaseki T; Tamura Y; Miyazaki A; Hirohashi Y; Torigoe T
    Cancer Med; 2023 Feb; 12(4):4605-4615. PubMed ID: 36200687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer.
    Chan JC; Hannan KM; Riddell K; Ng PY; Peck A; Lee RS; Hung S; Astle MV; Bywater M; Wall M; Poortinga G; Jastrzebski K; Sheppard KE; Hemmings BA; Hall MN; Johnstone RW; McArthur GA; Hannan RD; Pearson RB
    Sci Signal; 2011 Aug; 4(188):ra56. PubMed ID: 21878679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromodomain-containing protein 4 inhibition improves the efficacy of cisplatin and radiotherapy in oral squamous cell carcinoma by suppressing programmed cell death-ligand 1 expression.
    Ren J
    Basic Clin Pharmacol Toxicol; 2024 Feb; 134(2):272-283. PubMed ID: 38014458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
    Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
    Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of TNF-alpha/NFkB/SIRT1 axis drives aggressiveness and cancer stem cells accumulation in chemoresistant oral squamous cell carcinoma.
    de Castro LR; de Oliveira LD; Milan TM; Eskenazi APE; Bighetti-Trevisan RL; de Almeida OGG; Amorim MLM; Squarize CH; Castilho RM; de Almeida LO
    J Cell Physiol; 2024 Feb; 239(2):e31164. PubMed ID: 38149816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/β-catenin pathway.
    Jang TH; Huang WC; Tung SL; Lin SC; Chen PM; Cho CY; Yang YY; Yen TC; Lo GH; Chuang SE; Wang LH
    J Biomed Sci; 2022 Jun; 29(1):42. PubMed ID: 35706019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
    Shen B; Huang D; Ramsey AJ; Ig-Izevbekhai K; Zhang K; Lajud SA; O'Malley BW; Li D
    Br J Cancer; 2020 Mar; 122(5):640-647. PubMed ID: 31853007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supramolecular nanodrug targeting CDK4/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma.
    Zhao B; Qin X; Fu R; Yang M; Hu X; Zhao S; Cui Y; Guo Q; Zhou W
    J Control Release; 2024 Apr; 368():623-636. PubMed ID: 38479445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
    Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway.
    Pai S; Yadav VK; Kuo KT; Pikatan NW; Lin CS; Chien MH; Lee WH; Hsiao M; Chiu SC; Yeh CT; Tsai JT
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.